NEW HAVEN, Conn. (WTNH) — In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and what treatments are available? Dr. Kunal Desai, ...

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease. Personalizing treatment for ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive ...

Please provide your email address to receive an email when new articles are posted on . Generalized myasthenia gravis (gMG) is a rare, chronic disorder in which the immune system produces muscle ...

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the ...

It's important to enhance MG treatment outcomes with strong provider-patient relationships and ongoing monitoring, explain Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD. There is a critical need ...

The FDA in April 2025 approved nipocalimab (Imaavy) as a treatment for people living with generalized myasthenia gravis (gMG). Specifically, nipocalimab is for people with gMG who are 12 and older and ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin ...

Buffalo, N.Y. -- Gil I. Wolfe, MD, Irvin and Rosemary Smith Professor and Chair of the Department of Neurology at the University at Buffalo School of Medicine and Biomedical Sciences, will play a ...

A new retrospective analysis compared clinical features of White, Hispanic, and African-American patients with MG who visited a single university-based clinic. After adjusting for covariates, the ...